Drugs / Cyclo-Z
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03560271 | Jun 2018 → Jun 2019 | type 2 diabetes mellitus | NovMetaPharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02784275 | Jun 2016 → May 2017 | type 2 diabetes mellitus | NovMetaPharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyclo-Z | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03560271 ↗ |
| Route | Oral | “The assigned dose will be orally administered to subjects once a day before bedtime for 12 consecutive weeks.” NCT02784275 ↗ |